LaunchTrends®: STELARA (ustekinumab)

A Series of Reports Tracking the Response to and Uptake to Centocor/Ortho-Biotech’s STELARA (ustekinumab) and its impact on the Dermatology Market

Study Overview:

LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products.  These report series provide information on how new products fit into the treatment algorithm, impact current therapies and change market dynamics.  They also provide information on awareness, familiarity, perceived clinical advantages and disadvantages of new products, and the promotional messages and activities of all market players. 

Methodology:

A total of three waves of research will occur.  In each wave, Dermatologists will complete a self-administered online survey, providing information about their perceptions, attitudes and usage of STELARA.  Following the survey, a subset of respondents will participate in qualitative phone interviews to probe into reasons for anticipated action or inaction as well as details surrounding the promotion of STELARA.

Sample Frame:

In each of the three waves, a random sample of 75 Dermatologists will participate in the online quantitative survey.  A subset of the survey respondents (n=20) will participate in each wave of the qualitative phone interviews. Each wave will consist of unique respondents.

Timing:

The wave one report is scheduled to publish on November 30, 2009. The following two waves will be fielded at three months and six months post launch.

Deliverables:

In addition to the three reports in power point format following each wave of the study (with tracking from prior waves), a complete set of frequency tables and summary statistics will be provided for each wave.  Onsite or web-cast presentations are available upon request at no charge.  Clients who purchase the report series are invited to include up to three proprietary questions in each wave at no additional charge.


For more information, please contact Sharon Funk at 610.363.3872 or This e-mail address is being protected from spambots. You need JavaScript enabled to view it